Metoprolol vs Carvedilol
## Overview
Metoprolol succinate and carvedilol are both cornerstone therapies for heart failure with reduced ejection fraction (HFrEF), but carvedilol has a fundamentally different pharmacological mechanism: it is a non-selective beta-blocker that also blocks alpha-1 adrenoceptors.
## Mechanism of Action
Metoprolol selectively blocks beta-1 receptors. Carvedilol blocks beta-1, beta-2, and alpha-1 receptors, producing combined negative chronotropic/inotropic effects (beta blockade) plus vasodilation (alpha-1 blockade). Carvedilol also has antioxidant properties.
## Pharmacokinetics
Both are CYP2D6-metabolized and lipophilic. Carvedilol bioavailability is ~25–35% and half-life 7–10 h (twice-daily dosing). Carvedilol is a racemate; the S(-)-enantiomer provides beta-blockade, while both enantiomers provide alpha-1 blockade.
## Pharmacodynamics and Clinical Evidence
Both have Class I recommendations for HFrEF. Carvedilol was studied in US Carvedilol Heart Failure Trials (4 trials, 65% mortality reduction in mild-moderate HF), COPERNICUS (severe HF), and CAPRICORN (post-MI LV dysfunction). Metoprolol was studied in MERIT-HF. The COMET trial directly compared carvedilol versus metoprolol tartrate (not succinate) and showed carvedilol superior, but methodological issues (different beta-blocker formulations and potentially inequivalent doses) make direct comparison controversial.
## Alpha-1 Blockade Effects
Carvedilol's alpha-1 blockade produces vasodilation, lowering peripheral resistance and afterload. This can cause more first-dose hypotension than metoprolol. However, the vasodilatory effect may provide additive benefit in hypertensive HF patients.
## Key Takeaways
- Carvedilol: non-selective + alpha-1 blockade; vasodilating; more hypotension risk
- Metoprolol XL: selective beta-1; well-studied; less first-dose hypotension
- Both Class I for HFrEF; carvedilol may have additional antioxidant/anti-remodeling benefit
- Both contraindicated in severe decompensated HF (initiate only in stable HF)
Sonuç
Both metoprolol succinate XL and carvedilol are recommended first-line agents for HFrEF. Carvedilol may be preferred in hypertensive HF patients where afterload reduction is additional benefit. Metoprolol XL is preferred in patients with reactive airway disease, as carvedilol's beta-2 blockade is contraindicated in asthma.